<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tumor, node, metastasis (TNM) staging system for lung cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tumor, node, metastasis (TNM) staging system for lung cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tumor, node, metastasis (TNM) staging system for lung cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karl W Thomas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael K Gould, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The tumor, node, metastasis (TNM) staging system for lung cancer is an internationally accepted system used to characterize the extent of disease. The TNM system combines features of the tumor into stage groups that correlate with prognosis and are linked to treatment recommendations. The design criteria for stage classifications balance individual tumor characteristics as well as external priorities for applicability and implementation across international health systems. Specifically, criteria for stage classification include applicability across a broad spectrum of patients and geographic regions as well as simplicity and clarity [<a href="#rid1">1</a>].</p><p>This topic discusses the TNM staging system for lung cancer. The purpose of TNM staging is to provide a description of the anatomic extent of cancer that can be communicated to others, assist in treatment decisions, and indicate prognosis. Consistent application of staging criteria permits valid comparisons of patient cohorts, particularly in regards to the outcomes associated with different therapeutic options. In clinical practice, the links between stage, treatment, and prognosis are complex. For any individual patient, TNM stage should be combined with the unique clinical and socioeconomic characteristics of the patient, the molecular features of the tumor and treatment selections to guide the most accurate prognostic assessments.</p><p>The eighth edition of the TNM staging system and the evidence supporting it are described in this topic  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>) [<a href="#rid2">2,3</a>]. The eighth edition was effective internationally as of January 1, 2018. The clinical manifestations, diagnosis, pathology, and management of lung cancer are discussed in other topics.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4614.html" rel="external">"Treatment of refractory and relapsed small cell lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88587.html" rel="external">"Large cell neuroendocrine carcinoma of the lung"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a>.)</p><p></p><p class="headingAnchor" id="H905655765"><span class="h1">PATHOLOGIC, CLINICAL AND OTHER STAGING DISTINCTIONS</span><span class="headingEndMark"> — </span>Different staging systems are used prior to and after surgical resection, as described below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical-diagnostic staging</strong> – Clinical-diagnostic staging (cTNM) is based primarily on imaging findings with or without additional information from minimally invasive biopsy procedures, such as endobronchial ultrasound-guided biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical-pathologic staging</strong> – TNM staging is described as surgical pathologic (pTNM) when it is based on findings combined from surgical resection or exploration of the primary tumor and lymph nodes with additional information from clinical imaging studies.</p><p></p><p class="bulletIndent1">The individual definitions of the T, N and M categories are the same whether assessed clinically or pathologically  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a>). The same TNM groupings are used to determine the clinical-diagnostic stage and surgical-pathologic stage, as well as retreatment stage and autopsy stage  (<a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>). The suffix "X" is attached (ie, TX, NX) if the extent of disease cannot be assessed for any of these features.</p><p></p><p class="headingAnchor" id="H350602179"><span class="h1">NSCLC VERSUS SCLC AND OTHER NEUROENDOCRINE CANCERS</span><span class="headingEndMark"> — </span>Lung cancer is clinically subclassified into two major categories based on a combination of clinical and pathologic features: non-small cell lung cancer (NSCLC) and small cell lung carcinoma (SCLC). NSCLC including the subtypes adenocarcinoma and squamous cell carcinoma is the most common tumor group by incidence rates. In practice, TNM staging is routinely applied to NSCLC without modification or clinical reclassifications.</p><p>SCLC comprises approximately 15 percent of all lung cancers. SCLC is a neuroendocrine carcinoma that has overlapping pathologic features with other rare tumors including large cell neuroendocrine carcinoma of the lung, as well as typical and atypical carcinoid tumors. Neuroendocrine tumors have distinctly different molecular, pathologic, and clinical features as well as treatment approaches when compared with NSCLC types. The utility of the staging system for SCLC and neuroendocrine tumors is complemented by additional classification in clinical treatment groups.</p><p>SCLC has been routinely approached using a two-stage classification system of clinical-limited or clinical-extensive disease. The origin of this approach is a historical classification scheme developed in part by the Veterans Administration Lung Study Group (VALSG) decades ago, which has been updated and internationally adopted [<a href="#rid4">4</a>]. The utility of this two-stage system is the simplicity of stage groupings by whether or not the tumor and regional nodes can be adequately covered in an effective radiation field. The eighth TNM staging system external validation data sets did include robust cohorts of 157,910 patients from the National Cancer Database and an additional 5002 patients from the International Association for the Study of Lung Cancer Database [<a href="#rid5">5</a>]. Although the TNM system derivation and validation cohorts included relatively few early stage SCLC cases, the TNM system is highly applicable to SCLC and provides more precision in classifying the disease than the two-stage system. To facilitate ongoing practical clinical care and to support ongoing development of registries and standardized clinical trials, a combined approach for staging SCLC using both the TNM staging system and the VALSG categories is recommended [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung", section on 'Staging'</a>.)</p><p>Similarly, rare neuroendocrine tumors including typical and atypical carcinoid tumors may be staged using the TNM classification system for lung cancer. In a cohort of 205 carcinoid tumors, the TNM system was predictive of survival and maintained clinical utility. However, in addition to the TNM factors of tumor size and nodal stage, the histology of the tumor (typical versus atypical) was also found to be highly predictive of recurrence and this factor should be considered in the initial assessment of pulmonary carcinoid tumors [<a href="#rid6">6</a>]. Additional factors particularly relevant to the management of lung carcinoid tumors include the feasibility of surgical resection based primarily on whether they arise proximally and involve large airways or are peripheral and surrounded by normal lung parenchyma. (See  <a class="medical medical_review" href="/z/d/html/85914.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">EIGHTH EDITION OF THE TNM SYSTEM</span><span class="headingEndMark"> — </span>The eighth edition was a planned revision of the previous edition to incorporate new survival data gained from advances in imaging techniques, clinical testing, and therapeutics [<a href="#rid3">3</a>].</p><p>To inform the eighth edition of the TNM staging system, the International Association for the Study of Lung Cancer developed a database of approximately 95,000 diverse patients with lung cancer who were treated in 16 countries between 1999 and 2010  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>) [<a href="#rid1">1,2,7</a>]. Data from 70,967 patients with non-small cell lung cancer were used to retrospectively validate the prognostic value of the TNM descriptors [<a href="#rid1">1</a>].</p><p>As with previous editions, the current edition of the TNM staging system categorizes tumors on the basis of primary tumor characteristics (T), the presence or absence of regional lymph node involvement (N), and the presence or absence of distant metastases (M). Molecular tumor features of lung cancer are not included in the TNM system. The overall stage of the tumor (stage I through IV) is determined by the combination of T, N, and M descriptors  (<a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3401309595"><span class="h2">Prognosis by stage</span><span class="headingEndMark"> — </span>Under the eighth edition of the TNM staging system, the median survival correlates with both the clinical stage and surgical-pathologic stage. The survival according to clinical and pathologic staging for the eighth edition is shown in the figures  (<a class="graphic graphic_figure graphicRef110571" href="/z/d/graphic/110571.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef110573" href="/z/d/graphic/110573.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H2318371311"><span class="h2">Primary tumor (T) classification</span><span class="headingEndMark"> — </span>The primary distinction between T classification categories is tumor size. Other features, including invasion of proximal airways, mediastinal involvement, pleural involvement, and extension through the diaphragm or chest wall, also define distinct prognostic categories and correlate with surgical resectability. Combined, these features may be grouped into distinct prognostic categories  (<a class="graphic graphic_figure graphicRef110537" href="/z/d/graphic/110537.html" rel="external">figure 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tx</strong> - Primary tumor cannot be assessed or tumor proven by presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T0</strong> – No evidence of primary tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tis</strong> – Carcinoma in situ.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T1</strong> – <strong>Tumor ≤3 cm in greatest dimension</strong> surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the main bronchus).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T1a(mi) – Minimally invasive adenocarcinoma (solitary adenocarcinoma, ≤3 cm with a predominately lepidic pattern and ≤5 mm invasion in any one focus)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T1a – Tumor ≤1 cm in greatest dimension</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T1b – Tumor &gt;1 but ≤2 cm in greatest dimension</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T1c – Tumor &gt;2 but ≤3 cm in greatest dimension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T2</strong> - <strong>Tumor &gt;3 but ≤5 cm</strong> or tumor with any of the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Involves main bronchus regardless of distance from the carina but without involvement of the carina</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Invades visceral pleura but does not extend beyond visceral pleural surface</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>T2a</strong> – Tumor &gt;3 but ≤4 cm in greatest dimension</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>T2b</strong> – Tumor &gt;4 but ≤5 cm in greatest dimension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T3</strong> - <strong>Tumor &gt;5 but ≤7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in the same lobe as the primary tumor or directly invades any of the following structures: chest wall (including the parietal pleura and superior sulcus tumors), phrenic nerve, and parietal pericardium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T4</strong> - <strong>Tumor &gt;7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in a different ipsilateral lobe than that of the primary tumor or invades any of the following structures: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, and carina.</p><p></p><p class="headingAnchor" id="H983663957"><span class="h2">Regional lymph node (N) classification</span><span class="headingEndMark"> — </span>The lymph node classification is determined by the location of the lymph node in relationship to the primary tumor and hilum, mediastinum, and contralateral hilar regions [<a href="#rid8">8</a>]. As with the tumor designations, this classification correlates with survival  (<a class="graphic graphic_figure graphicRef110567" href="/z/d/graphic/110567.html" rel="external">figure 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Nx – Regional lymph nodes cannot be assessed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N0 – No regional lymph node metastasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N1 – Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph node(s) and intrapulmonary nodes, inducing involvement by direct extension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N2 – Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N3 – Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).</p><p></p><p>Although these N descriptors from the prior edition consistently predicted prognosis and were carried forward unchanged in the eighth edition, an exploratory subclassification of pathologic (surgically staged) N1 and N2 disease based on the number of involved nodal stations and individual nodes has been proposed  (<a class="graphic graphic_figure graphicRef110567" href="/z/d/graphic/110567.html" rel="external">figure 4</a>) [<a href="#rid3">3,9</a>]. However, these subcategories of the N descriptors have not been formally incorporated into the staging system.</p><p class="bulletIndent1"><span class="glyph">●</span>pN1 – Involvement of ipsilateral intrapulmonary, peribronchial, or hilar lymph nodes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pN1a – Single-station metastasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pN1b – Multiple-station metastasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pN2 – Involvement of ipsilateral mediastinal or subcarinal lymph nodes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pN2a1 – Single N2 station without concurrent N1 station involvement (skip metastasis).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pN2a2 – Single N2 station with concurrent N1 involvement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pN2b – Multiple N2 station metastasis.</p><p></p><p class="headingAnchor" id="H3048853809"><span class="h2">Distant metastasis (M) classification</span><span class="headingEndMark"> — </span>The primary determinants of prognosis in patients with metastatic disease are determined by the presence of metastasis within the thorax, extrathoracic metastasis, and the presence of malignant pericardial or pleural effusions  (<a class="graphic graphic_figure graphicRef110568" href="/z/d/graphic/110568.html" rel="external">figure 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>M0 – No distant metastasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>M1 – Distant metastasis present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>M1a – Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s) or malignant pleural or pericardial effusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>M1b – Single extrathoracic metastasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>M1c – Multiple extrathoracic metastasis in one or more organs.</p><p></p><p>The eighth edition of the TNM staging created a new category, M1b, designating a single extrathoracic metastasis, which is distinguished from M1c, in which there are multiple metastatic lesions (in one or multiple organs  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a>)). These changes led to the designation of stage IVA disease, in which disease is limited to either intrathoracic metastatic involvement or a single extrathoracic metastasis, versus stage IVB disease, in which multiple extrathoracic metastases exist. It is intended that this degree of precision will ultimately help guide treatment options for oligometastatic disease. (See  <a class="medical medical_review" href="/z/d/html/97507.html" rel="external">"Oligometastatic non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a>.)</p><p class="headingAnchor" id="H972402740"><span class="h2">Stage groupings</span><span class="headingEndMark"> — </span>Stage groupings reflect prognosis groupings whether clinically or pathologically staged. The eighth edition TNM staging system has refined the stage groupings by increasing the number of stage subcategories  (<a class="graphic graphic_figure graphicRef110571" href="/z/d/graphic/110571.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef110573" href="/z/d/graphic/110573.html" rel="external">figure 2</a> and <a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>). As an example, a new disease category stage IIIC was created for patients with N3 disease and either a T3 or T4 primary lesion [<a href="#rid2">2</a>]. This category reflects the poor prognosis of such cancers relative to stage IIIB cancers. Although the prognosis for stage IIIC disease is similar to stage IV disease, the distinction is made due to different treatment approaches available for locally advanced, nonmetastatic disease. Similarly, categories for stage IVA and IVB, as well as for IA1, IA2, and IA3 were developed as prognostic differences and became statistically significant. (See  <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer", section on 'Clinical mediastinal (N2, N3) involvement'</a> and  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/891.html" rel="external">"Patient education: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The tumor, node, metastasis (TNM) staging system for lung cancer is an internationally accepted system used to characterize the extent of disease. The purpose of TNM staging is to provide a description of the extent of cancer that can be easily communicated to others, assist in treatment decisions, and serve as a prognostic indicator. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The TNM staging system relies on anatomic, macroscopic groupings of disease with similar prognoses rather than on molecular characterization. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eighth edition of the TNM system</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The TNM staging system predicts survival, but should not be used alone to dictate treatment. Patient specific factors and health system resources must be considered. (See <a class="local">'Eighth edition of the TNM system'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most recent version of the TNM staging system is the eighth edition of the "TNM Classification of Malignant Tumors," effective internationally as of January 1, 2018. The eighth edition preserved the majority of features in the prior systems, but refined and subclassified tumor stage groupings, as well as T and M descriptors  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110964" href="/z/d/graphic/110964.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The eighth edition emphasizes size cutoffs, such that there are distinct categories for each centimeter increase in size from 1 to 5 cm. (See <a class="local">'Primary tumor (T) classification'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For N descriptors the eighth edition makes the recommendation to quantify nodal disease by the number of involved nodal stations; however, it stops short of formally including this in the subsequent stage groupings. (See <a class="local">'Regional lymph node (N) classification'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Metastatic disease is divided according to whether metastatic disease is limited to the chest, and if not, whether there are single or multiple extrathoracic sites of metastasis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stage groupings reflect combinations of T, N, and M factors, which have similar prognosis and treatment approaches. Subcategories of stage reflect further refinements of prognosis based on specific T, N, or M features.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Detterbeck FC, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2016; 11:1433.</a></li><li><a class="nounderline abstract_t">Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39.</a></li><li class="breakAll">American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2017.</li><li><a class="nounderline abstract_t">Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5:119.</a></li><li><a class="nounderline abstract_t">Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2017; 12:1109.</a></li><li><a class="nounderline abstract_t">Dermawan JK, Farver CF. The Prognostic Significance of the 8th Edition TNM Staging of Pulmonary Carcinoid Tumors: A Single Institution Study With Long-term Follow-up. Am J Surg Pathol 2019; 43:1291.</a></li><li><a class="nounderline abstract_t">Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151:193.</a></li><li><a class="nounderline abstract_t">Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:568.</a></li><li><a class="nounderline abstract_t">Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10:1675.</a></li></ol></div><div id="topicVersionRevision">Topic 4602 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27448762" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26762738" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26762738" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Staging and prognostic factors in small cell lung cancer: a consensus report</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461257" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31094922" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Prognostic Significance of the 8th Edition TNM Staging of Pulmonary Carcinoid Tumors: A Single Institution Study With Long-term Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780786" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Eighth Edition Lung Cancer Stage Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357537" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26709477" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
